Sort

Search

13/11/2023 Sensitization to avian and fungal proteins in different work environments
Sánchez-Díez, S, Muñoz, X, Montalvo, T, Ojanguren, I, Romero-Mesones, C, Senar, JC, Peracho-Tobena, V, Cruz, MJ. Sensitization to avian and fungal proteins in different work environments. Allergy Asthma and Clinical Immunology. 2023; 19(1)DOI:10.1186/s13223-023-00852-w. PMID:37957771. IF:2.600(Q2/5D).
10/11/2023 Impact of the MEESSI-AHF tool to guide disposition decision-making in patients with acute heart failure in the emergency department: a before-and-after study
Mirò, O, Llorens, P, Rosselló, X, Gil, V, Sánchez, C, Jacob, J, Herrero-Puente, P, López-Diez, MP, Llauger, L, Romero, R, Fuentes, M, Tost, J, Bibiano, C, Alquézar-Arbé, A, Martín-Mojarro, E, Bueno, H, Peacock, F, Martin-Sanchez, FJ, Pocock, S. Impact of the MEESSI-AHF tool to guide disposition decision-making in patients with acute heart failure in the emergency department: a before-and-after study. EMERGENCY MEDICINE JOURNAL. 2023; 41(1)DOI:10.1136/emermed-2023-213190. PMID:37949639. IF:2.800(Q1/2D).
09/11/2023 Replacing a kidney biopsy by exome sequencing in undetermined kidney diseases-not yet ready for prime time!
Torra, R, Kronbichler, A, Bajema, IM. Replacing a kidney biopsy by exome sequencing in undetermined kidney diseases-not yet ready for prime time!. Clinical Kidney Journal. 2023; 17(1)DOI:10.1093/ckj/sfad250. PMID:38186890. IF:3.900(Q1/2D).
09/11/2023 The influence of general practitioner and patient sex on the treatment of major depression
Jufresa-Blanch, E, Carrilero, N, García-Altés, A. The influence of general practitioner and patient sex on the treatment of major depression. Frontiers in Pharmacology. 2023; 14DOI:10.3389/fphar.2023.1274774. PMID:38027028. IF:4.400(Q1/2D).
09/11/2023 Comprehensive vasodilatation in women with acute heart failure: Novel insights from the GALACTIC randomized controlled trial
Wussler, D, Belkin, M, Maeder, MT, Walter, J, Shrestha, S, Kupska, K, Stierli, M, Flores, D, Kozhuharov, N, Gualandro, DM, de Oliveira, MT Jr, Sabti, Z, Noveanu, M, Socrates, T, Bayés-Genis, A, Sionis, A, Simon, P, Michou, E, Gujer, S, Gori, T, Wenzel, P, Pfister, O, Arenja, N, Kobza, R, Rickli, H, Breidthardt, T, Münzel, T, Mueller, C, GALACTIC Investigators. Comprehensive vasodilatation in women with acute heart failure: Novel insights from the GALACTIC randomized controlled trial. EUROPEAN JOURNAL OF HEART FAILURE. 2023; 25(12)DOI:10.1002/ejhf.3065. PMID:37871997. IF:16.900(Q1/1D).
08/11/2023 Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden
Santos-García, D, Fonticoba, TD, Bartolomé, CC, Painceiras, MJF, Díaz, IG, Alvarado, MCI, Paz, JM, Jesús, S, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Mayordomo, VG, Nogueira, V, García-Soto, JD, Borrué, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Mendoza, Z, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gastón, I, Kulisevsky, J, Seijo, M, Valero, C, Redondo, RA, Buongiorno, MT, Ordás, C, Menéndez-González, M, Mcafee, D, Martinez-Martin, P, Mir, P, COPPADIS Study Grp. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden. Brain and Behavior. 2023; 13(12)DOI:10.1002/brb3.3295. PMID:37939322. IF:2.600(Q2/3D).
06/11/2023 Assessment of a venous thromboembolism prophylaxis shared decision-making intervention (DASH-TOP) using the decisional conflict scale: a mixed-method study
León-García, M, Humphries, B, Morales, PR, Gravholt, D, Eckman, MH, Bates, SM, Suarez, NRE, Xie, F, Perestelo-Pérez, L, Alonso-Coello, P. Assessment of a venous thromboembolism prophylaxis shared decision-making intervention (DASH-TOP) using the decisional conflict scale: a mixed-method study. BMC Medical Informatics and Decision Making. 2023; 23(1)DOI:10.1186/s12911-023-02349-3. PMID:37932759. IF:3.300(Q2/5D).
06/11/2023 Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials
Yosipovitch, G, Lio, PA, Rosmarin, D, Serra-Baldrich, E, Legat, FJ, Casillas, M, Pierce, E, Liu, ZQ, Sun, LN, Elmaraghy, H, Ständer, S. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 190(2)DOI:10.1093/bjd/ljad435. PMID:37939793. IF:11.000(Q1/1D).